Protocol Ledger

NCT05904106 · Phase II · RECRUITING

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Interventional Phase II clinical trial protocol NCT05904106 sponsored by Technische Universität Dresden in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-07 Enrollment: 146 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05904106
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05904106
Protocol FieldVerified Registry Value
NCT IdentifierNCT05904106
Consolidated Lead SponsorTechnische Universität Dresden
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment146 participants (ESTIMATED)
Registered Start Date2024-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05904106
Hospital Research SiteLocationSite Profile
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->
Klinikum Chemnitz gGmbHChemnitz, GermanyOpen Hospital Dossier ->
Universitätsklinikum HeidelbergHeidelberg, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI